Sign up now to have the right to view
50 tenders for free.
Contract Details
| Title |
Brineura 150 Mg Solution For Infusion Slovakia |
|||
|---|---|---|---|---|
You can sign up and unlock it for freeAccess to Public and Private Sector Business Opportunities for 200+ Countries |
||||
| Country | ||||
| Language | English | |||
| Organization | ||||
| Published Date | 28.08.2024 | |||
| Awarded Date | 11.04.2019 | |||
| Overview | Contract Award's Details : Brineura 150 Mg Solution For Infusion Detská Fakultná Nemocnica S Poliklinikou Banská Bystrica 37957937 Námestie L.Svobodu 4 Banská Bystrica 974 09 Slovakia Contact Person: Ing. Gabriela Gondová Tel: +421 915577656 E-Mail: Obstaravanie@Dfnbb.Sk Fax: +421 48472 Brineura 150 Mg Solution For Infusion Voluntary ex ante transparency notice: Brineura 150 mg solution for infusion () brineura 150 mg solution for infusion (sukl 4681c) contains the active substance cerliponase alfa, Which belongs to a group of medicines known as enzyme replacement therapy. Brineura (cerliponase alfa) is the first approved treatment for any form of batten~s disease and is indicated to slow disease progression in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (cln2), Also known as tripeptidyl deficiency peptidase 1 (tpp1). Cln2 is an extremely rare and rapidly developing brain disorder that affects approximately 20 children born in the united states per year, Less than 1 disease per million americans. Brineura is the first enzyme replacement therapy that is administered directly to the brain fluid that treats the underlying cause of cln2 by helping to replace the missing tpp1 enzyme in affected children. It is used to treat patients with neuronal ceroid lipofuscinosis type 2 (cln2), Also known as tripeptidyl peptidase 1 (tpp1) deficiency. Cln2 disease is a rare genetic disorder that affects children. People with cln2 have little or no enzyme called tpp1, Which causes the accumulation of substances called lysosomal storage substances. In people with cln2, These substances accumulate in some parts of the body, Especially in the brain. This drug replaces the missing enzyme called tppa, Thereby minimizing the accumulation of lysosomal storage substances. This medicine works by slowing the progress of the disease. The recommended dose is 300 mg of cerliponase alfa given once every two weeks by intracerebroventricular infusion, Which means that it is administered to the cerebrospinal fluid by infusion through a surgically implanted reservoir and catheter. Initial estimated total value of the contract: /lot/concession 570 931.94 eurtotal value of the contract/lot/concession 570 931.94 eurv.2.5)information about subcontractingsection vi complementary information Initial estimated total value of the contract/lot/concession: 570 931.94 EUR Slovakia Contract value : See in details Contractors : TRANSMEDIC SLOVAKIA, S.R.O See in details 12/04/2019 11/07/2019 13130047 12/04/2019 Detská Fakultná Nemocnica S Poliklinikou Banská Bystrica 37957937 Námestie L.Svobodu 4 Banská Bystrica 974 09 Slovakia Contact Person: Ing. Gabriela Gondová Tel: +421 915577656 E-Mail: Obstaravanie@Dfnbb.Sk Fax: +421 48472 Address : Slovakia Slovakia Contract Awards Slovakia 170355-2019 See in details 11/07/2019 See in details | |||
| NAICS |
-
|
|||
| CPVS | ||||
| UNSPSC |
-
|
|||
| Regions | ||||
| Sectors |
Healthcare and Medicine
Automobiles and Auto Parts
Non-Renewable Energy
Supply
Solar Photovoltaic PV Energy
Roads and Highways-Bridge
Law and Legal
Printing and Publishing
Cement and Asbestos Products
Railways-Rail-Railroad
Defence and Security
Electricity
Construction
Energy-Power and Electrical
Computer Hardwares and Consumables
Steel
Aviation
Construction Materials
Marine
|
|||
| Contractor | ||||
| Contract Value |
See in details
|
URL | ||
| Share | ||||
Slovakia
| Title |
|---|
Brineura 150 Mg Solution For Infusion Slovakia |
| Country |
| Language |
| English |
| Organization |
| Published Date |
| 28.08.2024 |
| Awarded Date |
| 11.04.2019 |
| Overview |
| Contract Award's Details : Brineura 150 Mg Solution For Infusion Detská Fakultná Nemocnica S Poliklinikou Banská Bystrica 37957937 Námestie L.Svobodu 4 Banská Bystrica 974 09 Slovakia Contact Person: Ing. Gabriela Gondová Tel: +421 915577656 E-Mail: Obstaravanie@Dfnbb.Sk Fax: +421 48472 Brineura 150 Mg Solution For Infusion Voluntary ex ante transparency notice: Brineura 150 mg solution for infusion () brineura 150 mg solution for infusion (sukl 4681c) contains the active substance cerliponase alfa, Which belongs to a group of medicines known as enzyme replacement therapy. Brineura (cerliponase alfa) is the first approved treatment for any form of batten~s disease and is indicated to slow disease progression in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (cln2), Also known as tripeptidyl deficiency peptidase 1 (tpp1). Cln2 is an extremely rare and rapidly developing brain disorder that affects approximately 20 children born in the united states per year, Less than 1 disease per million americans. Brineura is the first enzyme replacement therapy that is administered directly to the brain fluid that treats the underlying cause of cln2 by helping to replace the missing tpp1 enzyme in affected children. It is used to treat patients with neuronal ceroid lipofuscinosis type 2 (cln2), Also known as tripeptidyl peptidase 1 (tpp1) deficiency. Cln2 disease is a rare genetic disorder that affects children. People with cln2 have little or no enzyme called tpp1, Which causes the accumulation of substances called lysosomal storage substances. In people with cln2, These substances accumulate in some parts of the body, Especially in the brain. This drug replaces the missing enzyme called tppa, Thereby minimizing the accumulation of lysosomal storage substances. This medicine works by slowing the progress of the disease. The recommended dose is 300 mg of cerliponase alfa given once every two weeks by intracerebroventricular infusion, Which means that it is administered to the cerebrospinal fluid by infusion through a surgically implanted reservoir and catheter. Initial estimated total value of the contract: /lot/concession 570 931.94 eurtotal value of the contract/lot/concession 570 931.94 eurv.2.5)information about subcontractingsection vi complementary information Initial estimated total value of the contract/lot/concession: 570 931.94 EUR Slovakia Contract value : See in details Contractors : TRANSMEDIC SLOVAKIA, S.R.O See in details 12/04/2019 11/07/2019 13130047 12/04/2019 Detská Fakultná Nemocnica S Poliklinikou Banská Bystrica 37957937 Námestie L.Svobodu 4 Banská Bystrica 974 09 Slovakia Contact Person: Ing. Gabriela Gondová Tel: +421 915577656 E-Mail: Obstaravanie@Dfnbb.Sk Fax: +421 48472 Address : Slovakia Slovakia Contract Awards Slovakia 170355-2019 See in details 11/07/2019 See in details |
| NAICS |
| - |
| CPVS |
| Tanks, reservoirs, containers and pressure vessels Reservoirs Forms Enzymes Catheters |
| UNSPSC |
| - |
| Regions |
| Eastern Europe Europe |
| Sectors |
| Healthcare and Medicine Automobiles and Auto Parts Non-Renewable Energy Supply Solar Photovoltaic PV Energy Roads and Highways-Bridge Law and Legal Printing and Publishing Cement and Asbestos Products Railways-Rail-Railroad Defence and Security Electricity Construction Energy-Power and Electrical Computer Hardwares and Consumables Steel Aviation Construction Materials Marine |
| Contractor |
| Contract Value |
|
See in details
|
| URL |
|
|
| Share |
To be notified
when a tender matching your filter is
published
To Follow
Tenders
Add New Tender Alert
To Follow
Contracts
Add New Contract Alert
To Follow
Fairs
Add New Fair Alert
Similar Contracts